Antares pharma inc.
Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in ...
Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas.Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in ...Pipeline :: Antares Pharma. Halozyme has completed its acquistion of Antares Pharma, creating a leading drug delivery business. View details here.ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) _____ Delaware: 001-32302: 41-1350192 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 100 Princeton South, Suite 300, Ewing, NJ ...Antares Pharma Inc. Temple University - Fox School of Business and Management Report this profile About A senior pharmaceutical executive with over 20 years experience in operations, finance ...
View Antares Pharma, Inc. Marketing Contacts, Executives, Media Spend, Marketing Technologies and Brands. Open doors with marketers, their agencies and the ...May 6, 2021 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in ...
Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures, and commercializes, for itself or with partners, therapeutic products ...
Delaware . 1-32302 . 41-1350192 (State or Other Jurisdiction. of Incorporation) (Commission. File Number) (I.R.S. Employer. Identification No.) 100 Princeton South ...Antares Pharma, Inc. (NASDAQ:ATRS) issued its quarterly earnings data on Thursday, November, 4th. The specialty pharmaceutical company reported $0.03 EPS for the quarter, meeting the consensus estimate of $0.03. The specialty pharmaceutical company earned $48.19 million during the quarter, compared to the consensus estimate of $48.52 million.Antares Pharma, Inc. develops pharmaceutical delivery systems, including needle-free and mini-needle injector systems and transdermal gel technologies. The Company …About us. About Antares Antares Pharma is a specialty pharmaceutical company that combines drug development expertise with proprietary delivery technology to deliver safe and effective...
Antares Pharma, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 41.56 million compared to USD 42.08 million a year ago. Net loss was USD 2.32 million compared to net income of USD 3.79 million a year ago. Basic loss per share from continuing operations …
On April 12, 2022, Antares Pharma, Inc., a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Halozyme Therapeutics, Inc., a Delaware corporation (“ Halozyme ”), and Atlas Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Halozyme ...
Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures, and commercializes, for itself …Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The companys injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA ...Drug Delivery Devices market - The market share is expected to increase by USD 77.26 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 6.28%. Dental Delivery Systems market - The market share has the potential to grow by USD 100.32 million during 2019-2023. The growth momentum will accelerate throughout ...Antares Pharma, Inc., a leader in self-injection drug delivery technology, announced the latest advancement in its proprietary line of VIBEX(TM) auto-injectors. Antares’ new VIBEX QS auto-injector platform offers a dose capacity of 1 mL and greater in a compact design. VIBEX QS achieves this advance by incorporating a novel triggering ...Tiberend Strategic Advisors, Inc. Jason Rando. (212) 827-0020. [email protected]. Share. Antares Pharma, Inc. (NYSE Amex: AIS) today announced that it has licensed to Pfizer Inc.’s Consumer Healthcare Business Unit one of its drug delivery technologies to develop an undisclosed product on an exclusive basis for North America.Jul 21, 2020 · Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...
Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures, and commercializes, for itself …The FDA has approved the oral drug estosterone undecanoate (Tlando; Antares Pharma, Inc) for testosterone replacement therapy (TRT) for conditions associated with a deficiency or absence of endogenous testosterone, or hypogonadism in adult patients. “The FDA approval of Tlando brings to market an oral formulation of testosterone that we believe …Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...About us. About Antares Antares Pharma is a specialty pharmaceutical company that combines drug development expertise with proprietary delivery technology to deliver safe and effective...Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures and commercializes, for itself or with partners, novel therapeutic …Pharmaceuticals, Inc. to make all required payments under the agreements; uncertainties regarding future FDA approval of TLANDO®, market acceptance and future revenue from the same, whether Antares will exercise the option for LPCN 1111 (TLANDO XR) and if exercised, future timing and success of the
Apr 13, 2022 ... Deal aims to expand Halozyme's drug delivery product portfolio for its pharmaceutical partners.Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...
Apr 13, 2022 · Halozyme Therapeutics Inc. agreed to a nearly $1 billion deal to buy specialty pharmaceutical company Antares Pharma Inc. in a move that will deepen its focus on drug delivery. Halozyme on ... As previously disclosed, on February 28, 2014, Antares Pharma, Inc. (“Antares”) sued Medac Pharma, Inc. (“Medac”) and its foreign parent, medac GmbH, in the United States District Court for the District of Delaware alleging infringement. Antares is asserting four patents. On March 14, 2014, Antares filed a motion for preliminary injunction seeking to …Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and …Becton, Dickinson and Company, Sanofi, Pfizer, Inc, Mylan N.V., Novartis AG, Bayer AG, Janssen Global Services, LLC, Antares Pharma, Inc., Amgen Inc, Eli Lilly and Company, Teva Pharmaceutical, Merck KgaA, GlaxoSmithKline plc, Ypsomed, SHL Medical, Gerresheimer AG, Midas Pharma GmbH, Aptar Pharma, Solteam Medical, …Antares Pharma announces FDA approval of Tlando™, an oral treatment for testosterone replacement therapy. News release. Antares Pharma Inc. Accessed March 29, 2022.Antares Pharma, Inc. (“Antares” or the “Company”) is an emerging, specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. Antares has numerous partnerships with pharmaceutical companies as well as multiple internal product development programs.Apr 26, 2022 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in ... Apr 13, 2022 · SAN DIEGO and EWING, N.J., April 13, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") and Antares Pharma, Inc. (NASDAQ: ATRS) ("Antares") today announced that the...
Other vendors include Itelliject Inc, Adamis Pharmaceuticals Corp, Hospira Inc, Teva Pharmaceuticals Ltd and Antares Pharma Inc. Request a Free Sample. ... Inc. 201 Spear Street 1100, San Francisco, CA 94105, United States +1-415-349-0058 or 1-888-202-9519 [email protected] Business Hours . Our support available to help you 24 hours a day, five …
Antares Pharma, Inc. (Amex:AIS) has elected Leonard S. Jacob, M.D., Ph.D. to the Company ' s Board of Directors.. Dr. Leonard Jacob joins Antares with over 29 years of pharmaceutical industry experience including having founded InKine Pharmaceutical Company Inc. in 1997 and served as Chairman and CEO from its …
Delaware . 1-32302 . 41-1350192 (State or Other Jurisdiction. of Incorporation) (Commission. File Number) (I.R.S. Employer. Identification No.) 100 Princeton South ...23. 5. 2022 ...Antares Pharma, Inc. (NASDAQ:ATRS) issued its quarterly earnings data on Thursday, November, 4th. The specialty pharmaceutical company reported $0.03 EPS for the quarter, meeting the consensus estimate of $0.03. The specialty pharmaceutical company earned $48.19 million during the quarter, compared to the consensus estimate of $48.52 million.Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures, and commercializes, for itself …Antares Pharma Drug Portfolio. Antares Pharma focuses on the development and commercialization of self-administered pharmaceutical products and the technologies to deliver them. We have multiple internal product development programs, as well as partnerships with industry-leading pharmaceutical companies. Dec 15, 2021 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ... Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...Jul 21, 2020 · Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...
15. 4. 2022 ... The Details: Laura Cooper was first to report that Halozyme Therapeutics Inc. was close to acquiring specialty pharmaceutical company Antares ...Overview. Company Description: Antares Pharma understands antagonism towards needles. The company develops needle-free systems for administering injectable drugs. …A suit was filed on Wednesday in the Southern District of New York by investor Shiva Stein against defendants Antares Pharma, Inc., as well as the company’s board of directors. The complaint for ...Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures and commercializes, for itself or with partners, ...Instagram:https://instagram. intc buy or sellis gas prices going downwatchlist of stocksalternate investment platforms Antares Pharma, Inc. (ATRS.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Antares Pharma, Inc. | Nasdaq: ATRS ... vhy asxreits that pay monthly dividends Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...About Antares Pharma . Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures and commercializes, for itself or with partners, novel therapeutic ... schd ex dividend Antares Pharma Inc. announced that Ferring Pharmaceuticals Inc. has received U.S. Food and Drug Administration approval of a name change enabling its newly acquired recombinant human growth hormone to be marketed in the U.S. as ZOMACTON (somatropin [rDNA origin]) for injection, and the needle-free delivery system to be …Antares Pharma, Inc. (ATRS) is an emerging, specialty pharmaceutical company that focuses on the development and commercialization of self-administered …Follow. EWING, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug ...